Summary
Updated Aug 31, 2026
Daphne Karydas is Director of Mineralys Therapeutics, Inc. (MLYS). 5 SEC Form 4 filings on record going back to 2025, most recently on 18 June 2026. Most recent open-market trade: sold $75K of MLYS on 18 June 2026. Lifetime open-market sales: $840K.
Recent Transactions
8Every recent SEC Form 4 transaction Daphne Karydas has reported, most recent first.
Trading Pattern
InsiderAlpha's records for Daphne Karydas go back to 2025: 5 primary Form 4 filings, an average of 2.5 per year. 6 recorded transactions carry a Rule 10b5-1 flag, meaning they were pre-scheduled under a written trading plan rather than discretionary.
Other Insiders Active in the Same Stocks
Insiders who reported open-market trades in the last 12 months at the companies Daphne Karydas files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Brian Taylor Slingsby - $43.35M of MLYS open-market activity in the last 12 months
- RA CAPITAL MANAGEMENT, L.P. - $38.76M of MLYS open-market activity in the last 12 months
- Srinivas Akkaraju - $15.00M of MLYS open-market activity in the last 12 months
- Jon Congleton - $14.38M of MLYS open-market activity in the last 12 months
- Adam Scott Levy - $5.82M of MLYS open-market activity in the last 12 months
- David Malcom Rodman - $5.28M of MLYS open-market activity in the last 12 months
More Notable Insiders
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
Frequently Asked Questions
Who is Daphne Karydas?
Daphne Karydas is a corporate insider, tracked as Director of Mineralys Therapeutics, Inc. (MLYS). InsiderAlpha holds 5 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Daphne Karydas submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.
Has Daphne Karydas been buying or selling stock?
Recorded transactions: 0 open-market purchases and 4 open-market sales ($840K) across all tracked filings.
Where can I see all of Daphne Karydas's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Learn More
Follow Daphne Karydas and every insider like them
A free account opens the full scored daily plan and every past day, a watchlist for any ticker, and 3 months of price history on every company page. No card.
Free plan available · Paid plans start with a 7-day free trial